Posted by Michael Wonder on 05 Apr 2023
Ipsen reacts to NICE’s Cabometyx verdict
5 April 2023 - Company disappointed by institute’s failure to recommend thyroid cancer therapy for specific patient group
Ipsen has expressed its disappointed regarding NICE's preliminary guidance which does not recommend Cabometyx – also known as cabozantinib.
